EGFR and cancer: A recent study has shown simultaneous inhibition of HDAC and receptor tyrosine kinases (epidermal growth factor receptor—EGFR—and human epidermal growth factor receptor 2—HER2) in cancer cells, and displayed antiproliferative and proapoptotic activities in vitro as well as in drug-resistant in vivo tumor models [91].